A Phase I/II Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; HYD Sulfate) in Children With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

Trial Profile

A Phase I/II Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; HYD Sulfate) in Children With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Aug 2018

At a glance

  • Drugs Selumetinib (Primary)
  • Indications Neurofibromatoses; Plexiform neurofibroma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms SPRINT
  • Most Recent Events

    • 13 Jul 2018 Planned primary completion date changed from 10 Sep 2019 to 10 Sep 2020.
    • 05 Jun 2018 Results (n=50) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 16 May 2018 According to a Merck & Co media release, data from this trial will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top